Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

Inclusion Criteria:

Adult patients:

• At least 18 years of age

• Self-reports having been diagnosed with 1 of the following syndromes:

• Klippel-Trenaunay Syndrome (KTS)

• Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi,Scoliosis/Skeletal and spinal (CLOVES syndrome)

• Isolated Lymphatic Malformation (ILM)

• Megalencephaly-Capillary Malformation (MCAP or M-CM)

• Hemimegalencephaly (HME)/Dysplastic Megalencephaly (DMEG)/Focal corticaldysplasia type II

• Hemihyperplasia-Multiple Lipomatosis (HHML)

• Facial Infiltrating Lipomatosis (FIL)

• Fibroadipose Vascular Anomaly (FAVA)

• Macrodactyly

• Hemihyperplasia (Muscular HH)

• Fibroadipose hyperplasia or Overgrowth (FAO)

• Capillary malformation of the lower lip, Lymphatic malformation of the face andneck, Asymmetry of the face and limbs, and Partial or generalized Overgrowth (CLAPO syndrome)

• Epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis

• Able to converse and read/answer survey questions in English

• Willing and able to provide informed consent

Adolescent patients

• Between the ages of 12 and 17 years

• Self-reports having been diagnosed with one of the following syndromes:

• Klippel-Trenaunay Syndrome (KTS)

• Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi,Scoliosis/Skeletal and spinal (CLOVES syndrome)

• Isolated Lymphatic Malformation (ILM)

• Megalencephaly-Capillary Malformation (MCAP or M-CM)

• Hemimegalencephaly (HME)/Dysplastic Megalencephaly (DMEG)/Focal corticaldysplasia type II

• Hemihyperplasia-Multiple Lipomatosis (HHML)

• Facial Infiltrating Lipomatosis (FIL)

• Fibroadipose Vascular Anomaly (FAVA)

• Macrodactyly

• Hemihyperplasia (Muscular HH)

• Fibroadipose hyperplasia or Overgrowth (FAO)

• Capillary malformation of the lower lip, Lymphatic malformation of the face andneck, Asymmetry of the face and limbs, and Partial or generalized Overgrowth (CLAPO syndrome)

• Epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis

• Able to converse and read/answer survey questions in English independently, asassessed by guardian

• Willing and able to provide assent

• Has a parent/legal guardian who is able and willing to provide permission for theadolescent to participate

Caregivers

• At least 18 years of age

• Is the parent/legal guardian of a child/adolescent who has been diagnosed with oneof the following syndromes:

• Klippel-Trenaunay Syndrome (KTS)

• Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi,Scoliosis/Skeletal and spinal (CLOVES syndrome)

• Isolated Lymphatic Malformation (ILM)

• Megalencephaly-Capillary Malformation (MCAP or M-CM)

• Hemimegalencephaly (HME)/Dysplastic Megalencephaly (DMEG)/Focal corticaldysplasia type II

• Hemihyperplasia-Multiple Lipomatosis (HHML)

• Facial Infiltrating Lipomatosis (FIL)

• Fibroadipose Vascular Anomaly (FAVA)

• Macrodactyly

• Hemihyperplasia (Muscular HH)

• Fibroadipose hyperplasia or Overgrowth (FAO)

• Capillary malformation of the lower lip, Lymphatic malformation of the face andneck, Asymmetry of the face and limbs, and Partial or generalized Overgrowth (CLAPO syndrome)

• Epidermal nevus, benign lichenoid keratosis, or seborrheic keratosis

• Child is either between the ages of 5 and 11 (inclusive), or between the ages of 12and 17 years (inclusive) but is unable to self-report due to cognitive difficulties

• Able to converse and read/answer survey questions in English

• Willing and able to provide informed consent

Exclusion Criteria:

There are no specific exclusion criteria. However, participants may be excluded if the quota related to alpelisib treatment (60 treated with alpelisib; 40 not treated with alpelisib) has been achieved. For example, if 40 participants not treated with alpelisib have been recruited into the study, any additional participants not treated with alpelisib will be excluded. Patients treated with alpelisib may be similarly excluded if the quota of 60 patients has already been achieved.